Brokerages expect that Omeros (NASDAQ:OMER) will report $2.59 million in sales for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Omeros’ earnings. The lowest sales estimate is $1.97 million and the highest is $3.20 million. Omeros reported sales of $17.15 million during the same quarter last year, which would suggest a negative year-over-year growth rate of 84.9%. The firm is expected to announce its next quarterly earnings report on Tuesday, August 14th.
On average, analysts expect that Omeros will report full year sales of $18.22 million for the current year, with estimates ranging from $9.63 million to $26.80 million. For the next fiscal year, analysts expect that the firm will post sales of $99.08 million per share, with estimates ranging from $27.46 million to $170.70 million. Zacks’ sales averages are an average based on a survey of analysts that follow Omeros.
Omeros (NASDAQ:OMER) last announced its quarterly earnings results on Thursday, May 10th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.05). The firm had revenue of $1.59 million for the quarter, compared to the consensus estimate of $2.08 million. During the same period last year, the business earned ($0.34) earnings per share. The firm’s revenue for the quarter was down 87.0% compared to the same quarter last year.
Several equities analysts have recently issued reports on the stock. Wedbush reissued a “hold” rating and issued a $20.00 price target (up previously from $19.00) on shares of Omeros in a report on Wednesday, May 16th. Maxim Group set a $25.00 price target on shares of Omeros and gave the company a “buy” rating in a report on Sunday, May 13th. ValuEngine raised shares of Omeros from a “hold” rating to a “buy” rating in a report on Saturday, May 12th. HC Wainwright set a $34.00 price target on shares of Omeros and gave the company a “buy” rating in a report on Friday, May 11th. Finally, BidaskClub raised shares of Omeros from a “sell” rating to a “hold” rating in a report on Wednesday, May 9th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and four have assigned a buy rating to the stock. Omeros currently has a consensus rating of “Hold” and an average target price of $26.00.
Shares of Omeros opened at $19.84 on Friday, MarketBeat reports. Omeros has a 12-month low of $8.36 and a 12-month high of $27.09. The firm has a market capitalization of $1.00 billion, a PE ratio of -25.11 and a beta of 3.60. The company has a debt-to-equity ratio of -2.91, a current ratio of 3.19 and a quick ratio of 3.18.
In related news, VP Michael A. Jacobsen sold 23,792 shares of the company’s stock in a transaction on Tuesday, May 15th. The shares were sold at an average price of $23.80, for a total value of $566,249.60. Following the completion of the transaction, the vice president now directly owns 19,480 shares of the company’s stock, valued at approximately $463,624. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 12.10% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Wedbush Securities Inc. boosted its stake in Omeros by 32.4% in the 4th quarter. Wedbush Securities Inc. now owns 94,923 shares of the biopharmaceutical company’s stock worth $1,844,000 after purchasing an additional 23,241 shares during the period. Wells Fargo & Company MN boosted its stake in Omeros by 73.4% in the 4th quarter. Wells Fargo & Company MN now owns 73,059 shares of the biopharmaceutical company’s stock worth $1,419,000 after purchasing an additional 30,915 shares during the period. Baird Financial Group Inc. boosted its stake in Omeros by 9.0% in the 4th quarter. Baird Financial Group Inc. now owns 62,296 shares of the biopharmaceutical company’s stock worth $1,210,000 after purchasing an additional 5,151 shares during the period. State of Wisconsin Investment Board boosted its stake in Omeros by 93.9% in the 4th quarter. State of Wisconsin Investment Board now owns 44,600 shares of the biopharmaceutical company’s stock worth $867,000 after purchasing an additional 21,600 shares during the period. Finally, Capital Analysts LLC boosted its stake in Omeros by 885.6% in the 4th quarter. Capital Analysts LLC now owns 590,849 shares of the biopharmaceutical company’s stock worth $36,125,000 after purchasing an additional 530,899 shares during the period. 46.37% of the stock is owned by hedge funds and other institutional investors.
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.